[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第9页

[Autologous stem cell transplantation after pola-BR regimen as a salvage therapy in relapsed diffuse large B-cell lymphoma]. 【pola-BR方案后自体干细胞移植作为复发弥漫性大b细胞淋巴瘤的补救性治疗】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.214

Kensuke Matsuda, Yosei Fujioka, Shinya Okuda, Koichi Sugimoto

引用次数: 0

[Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma]. [弥漫性大b细胞淋巴瘤的细胞动力学和tisagenleclear的预后]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.167

Ryo Hanajiri, Katsuya Furukawa, Marie Nakashima, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi

{"title":"[Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].","authors":"Ryo Hanajiri, Katsuya Furukawa, Marie Nakashima, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi","doi":"10.11406/rinketsu.64.167","DOIUrl":"https://doi.org/10.11406/rinketsu.64.167","url":null,"abstract":"CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promise as treatment of relapsed or refractory B-cell malignancies. However, the clinical utility of early CAR-T monitoring within 1 month after infusion has not been elucidated. In this study, we quantitatively measured CAR-T kinetics in peripheral blood on days 2, 4, 7, 9, 11, 14, 21, and 28 post-infusion using flow cytometry and quantitative polymerase chain reaction in 13 patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) treated with tisagenlecleucel (tisa-cel). No relationships were identified between bulk CAR-T kinetics and treatment outcomes. Interestingly, the magnitude of CD4+ CAR-T expansion was higher in responders than in nonresponders, while CD8+ CAR-T expansion was minimal in responders. Additionally, CAR-T proliferation was more pronounced in patients with cytokine release syndrome. Our results suggest that CD4+ CAR-T cellular kinetics within 1 month after CAR-T infusion may predict its efficacy after tisa-cel therapy in adult patients with DLBCL.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 3","pages":"167-174"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9612094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Overview]. (概述)。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.376

Takayuki Ikezoe

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.437

引用次数: 0

[Gene regulatory networks operated by iron-heme metabolism: focusing on the erythroid differentiation system]. [由铁血红素代谢操作的基因调控网络:聚焦于红细胞分化系统]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.406

Hiroki Kato, Kazuhiko Igarashi

{"title":"[Gene regulatory networks operated by iron-heme metabolism: focusing on the erythroid differentiation system].","authors":"Hiroki Kato, Kazuhiko Igarashi","doi":"10.11406/rinketsu.64.406","DOIUrl":"https://doi.org/10.11406/rinketsu.64.406","url":null,"abstract":"Recently, attention has been focused on how metabolites regulate cellular differentiation. Heme synthesis is greatly enhanced during erythroid differentiation. Heme is used for hemoglobin synthesis, which is needed for oxygen transport by red blood cells. Additionally, several pieces of evidence revealed that heme may control gene expression to fulfill erythroblast terminal maturation. For instance, heme binds to and inactivates the transcription factor BTB Domain And CNC Homolog 1 (BACH1), thereby inducing the globin gene expression, which is the repressive target of BACH1. Moreover, heme induces autophagy/mitophagy-related gene expressions, which are the targets of the transcription factor GATA1 and may promote erythrocyte maturation by itself. Heme may directly bind to guanine tetramer (G-quadruplex) regions of genomic DNA, thereby regulating nearby gene expressions. Here, we present an overview of the mechanism by which iron-heme metabolism regulates gene regulatory networks by focusing on the erythroid differentiation system. Additionally, we discuss the prospects of future research regarding iron-heme metabolism.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 5","pages":"406-410"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Utility of thromboelastography in the treatment of acquired hemophilia A]. [血栓弹性成像在获得性血友病治疗中的应用]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.338

Shuolin Wang, Keiki Nagaharu, Kazutaka Suzuki, Kensuke Hachiya, Komei Nishimura, Takeshi Matsumoto, Isao Tawara

引用次数: 0

[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria]. [日本患者对治疗阵发性夜间血红蛋白尿的ravulizumab和eculizumab的偏好]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.9

Ken Ishiyama, Kensuke Usuki, Takayuki Ikezoe, Akihiko Gotoh, Karl-Johan Myren, Ioannis Tomazos, Akihiko Shimono, Haruhiko Ninomiya, Masatoshi Sakurai, Shinji Nakao, Jun-Ichi Nishimura

{"title":"[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].","authors":"Ken Ishiyama, Kensuke Usuki, Takayuki Ikezoe, Akihiko Gotoh, Karl-Johan Myren, Ioannis Tomazos, Akihiko Shimono, Haruhiko Ninomiya, Masatoshi Sakurai, Shinji Nakao, Jun-Ichi Nishimura","doi":"10.11406/rinketsu.64.9","DOIUrl":"https://doi.org/10.11406/rinketsu.64.9","url":null,"abstract":"Ravulizumab is the first long-acting complement inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH) treatment. We evaluated patient preference for ravulizumab or eculizumab among Japanese adults with PNH. The ALXN1210-PNH-301 (NCT02946463) and ALXN1210-PNH-302 (NCT03056040) studies included 23 Japanese adults who are enrolled in complement inhibitor treatment-naive and eculizumab (≥6 months) treatment. Patient preference was assessed using the PNH-specific patient preference questionnaire (PNH-PPQ©). Most patients preferred ravulizumab (19/23, 82.6%), none preferred eculizumab, and four (17.4%) reported no preference (χ2 test, p<0.005). The preference for ravulizumab was driven by its lower infusion frequency (every 8 weeks) compared with eculizumab (every 2 weeks). The included Japanese patients with PNH preferred ravulizumab because of its reduced infusion frequency, which increases activity planning ability, treatment convenience, and overall quality of life, as compared with eculizumab. These data provide useful insight into patient perspectives and may aid decision-making for PNH treatment.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 1","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma]. 弥漫性大b细胞淋巴瘤中枢神经系统复发的风险评估及预防治疗策略。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.490

Kana Miyazaki

引用次数: 0

[Posttransplant complications: GVHD and SOS/VOD]. [移植后并发症:GVHD和SOS/VOD]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.524

Yasuo Mori

{"title":"[Posttransplant complications: GVHD and SOS/VOD].","authors":"Yasuo Mori","doi":"10.11406/rinketsu.64.524","DOIUrl":"https://doi.org/10.11406/rinketsu.64.524","url":null,"abstract":"Several novel agents (e.g., molecularly targeted drug, bispecific antibody, antibody-drug conjugate, chimeric antigen receptor T-cell therapy) have successively emerged in clinical practice and are occasionally used in allogeneic hematopoietic cell transplantation (allo-HCT) settings. These drugs are expected to reduce pretransplant tumors, lower the risk of relapse with posttransplant maintenance therapy, and consequently improve transplant outcomes. Additionally, some molecularly targeted drugs could be adapted to treat steroid-refractory acute and/or chronic graft-versus-host disease (GVHD), which remained the leading cause of nonrelapse mortality after allo-HCT. However, these agents develop an excessive immune reaction, including GVHD, or presented an increased risk of sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) as their \"off-target\" effects. Thus, this review aimed to summarize the risk assessment and management of post-posttransplant complications, focusing on GVHD and SOS/VOD, in the era of molecularly targeted therapy. Moreover, recent advances in GVHD or SOS/VOD prophylaxis and treatment using novel agents/devices are also discussed.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 6","pages":"524-532"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Novel anti-complement therapeutics for hemolytic anemia]. [溶血性贫血的新型抗补体疗法]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.466

Jun-Ichi Nishimura

引用次数: 0